CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
-
Gang members given hundreds-years-long sentences in El Salvador
-
Chargers, Bills edge closer to playoff berths
-
Gang members given hundred-years-long sentences in El Salvador
-
Hosts Morocco off to winning start at Africa Cup of Nations
-
No jacket required for Emery as Villa dream of title glory
-
Amorim fears United captain Fernandes will be out 'a while'
-
Nigerian government frees 130 kidnapped Catholic schoolchildren
-
Captain Kane helps undermanned Bayern go nine clear in Bundesliga
-
Captain Kane helps undermanned Bayern go nine clear
-
Rogers stars as Villa beat Man Utd to boost title bid
-
Barca strengthen Liga lead at Villarreal, Atletico go third
-
Third 'Avatar' film soars to top in N. American box office debut
-
Third day of Ukraine settlement talks to begin in Miami
-
Barcelona's Raphinha, Yamal strike in Villarreal win
-
Macron, on UAE visit, announces new French aircraft carrier
-
Barca's Raphinha, Yamal strike in Villarreal win
-
Gunmen kill 9, wound 10 in South Africa bar attack
-
Allegations of new cover-up over Epstein files
-
Atletico go third with comfortable win at Girona
-
Schwarz breaks World Cup duck with Alta Badia giant slalom victory
-
Salah unaffected by Liverpool turmoil ahead of AFCON opener - Egypt coach
-
Goggia eases her pain with World Cup super-G win as Vonn takes third
-
Goggia wins World Cup super-G as Vonn takes third
-
Cambodia says Thai border clashes displace over half a million
-
Kremlin denies three-way US-Ukraine-Russia talks in preparation
-
Williamson says 'series by series' call on New Zealand Test future
-
Taiwan police rule out 'terrorism' in metro stabbing
-
Australia falls silent, lights candles for Bondi Beach shooting victims
-
DR Congo's amputees bear scars of years of conflict
-
Venison butts beef off menus at UK venues
-
Cummins, Lyon doubts for Melbourne after 'hugely satsfying' Ashes
-
'It sucks': Stokes vows England will bounce back after losing Ashes
-
Australia probes security services after Bondi Beach attack
-
West Indies need 462 to win after Conway's historic century
-
Thai border clashes displace over half a million in Cambodia
-
Australia beat England by 82 runs to win third Test and retain Ashes
-
China's rare earths El Dorado gives strategic edge
-
Japan footballer 'King Kazu' to play on at the age of 58
-
New Zealand's Conway joins elite club with century, double ton in same Test
-
Australian PM orders police, intelligence review after Bondi attack
-
Durant shines as Rockets avenge Nuggets loss
-
Pressure on Morocco to deliver as Africa Cup of Nations kicks off
-
Australia remove Smith as England still need 126 to keep Ashes alive
-
Myanmar mystics divine future after ill-augured election
-
From the Andes to Darfur: Colombians lured to Sudan's killing fields
-
Eagles win division as Commanders clash descends into brawl
-
US again seizes oil tanker off coast of Venezuela
-
New Zealand 35-0, lead by 190, after racing through West Indies tail
-
How Can Gum Disease Lead to Tooth Loss in Kyle, TX?
-
West Indies 420 all out to trail New Zealand by 155
NYSE - LSE
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York, NY.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information about the conference, please visit the conference website.
A video webcast of the presentation will be accessible for viewing on-demand beginning on Monday, September 8, 2025, at 7:00 AM ET for those registered for the event and will be accessible on the Events page in the Investors section of the Company's website (cnspharma.com). The webcast replay will be archived for 90 days following the event.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
[email protected]
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
C.Garcia--AMWN